Search research articles
Contact Us
Filters
Showing results (151-160 of 164) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies
Mayer N Fishman, Christopher R Garrett, George R Simon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Journal of Pediatric Rehabilitation Medicine
|
June 13, 2014
Transition and transfer of adolescents and young adults with pediatric onset chronic disease: the patient and parent perspective
Susan M Fernandes, Joanne O'Sullivan-Oliveira, Michael J Landzberg, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 13, 2025
Cognitive profiles at presentation and subsequent cognitive decline and quality of life in Parkinson's disease
Saira S Mirza, Sarah Duff-Canning, Mark Mapstone, et al.
Journal of Clinical and Experimental Neuropsychology
|
April 8, 2021
Bilingualism in Parkinson's disease: Relationship to cognition and quality of life
Keera N Fishman, Angela C Roberts, J B Orange, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Oncoimmunology
|
September 20, 2018
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
Michael Poch, MacLean Hall, Autumn Joerger, et al.
JAMA Oncology
|
August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Thomas Powles, Peter H O'Donnell, Christophe Massard, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 164) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies
Mayer N Fishman, Christopher R Garrett, George R Simon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Journal of Pediatric Rehabilitation Medicine
|
June 13, 2014
Transition and transfer of adolescents and young adults with pediatric onset chronic disease: the patient and parent perspective
Susan M Fernandes, Joanne O'Sullivan-Oliveira, Michael J Landzberg, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 13, 2025
Cognitive profiles at presentation and subsequent cognitive decline and quality of life in Parkinson's disease
Saira S Mirza, Sarah Duff-Canning, Mark Mapstone, et al.
Journal of Clinical and Experimental Neuropsychology
|
April 8, 2021
Bilingualism in Parkinson's disease: Relationship to cognition and quality of life
Keera N Fishman, Angela C Roberts, J B Orange, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Oncoimmunology
|
September 20, 2018
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
Michael Poch, MacLean Hall, Autumn Joerger, et al.
JAMA Oncology
|
August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Thomas Powles, Peter H O'Donnell, Christophe Massard, et al.
Page
of 17